Market closedNon-fractional
KalVista Pharmaceuticals/KALV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Ticker
KALV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
118
Website
www.kalvista.com
KALV Metrics
BasicAdvanced
$494M
Market cap
-
P/E ratio
-$3.14
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$494M
Beta
0.9
Financial strength
Current ratio
5.442
Quick ratio
5.19
Long term debt to equity
7.063
Total debt to equity
8.403
Management effectiveness
Return on assets (TTM)
-42.50%
Return on equity (TTM)
-79.33%
Valuation
Price to book
4.6
Price to tangible book (TTM)
4.6
Price to free cash flow (TTM)
-4.157
Growth
Earnings per share change (TTM)
-11.68%
3-year earnings per share growth
14.08%
What the Analysts think about KALV
Analyst Ratings
Majority rating from 6 analysts.
KALV Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$29M
5.07%
Profit margin
0.00%
NaN%
KALV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.77
-$0.74
-$0.80
-$0.84
-
Expected
-$0.94
-$0.86
-$0.79
-$0.77
-$0.73
Surprise
-17.94%
-13.79%
1.73%
9.49%
-
KALV News
AllArticlesVideos
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Seeking Alpha·2 weeks ago
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
Business Wire·3 weeks ago
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $494M as of July 05, 2024.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of July 05, 2024.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell KalVista Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.